RTP Mobile Logo
Proceedings from the Second Annual Miami General Medical Oncology Symposium
Released April 2020

Proceedings from a weekend-long symposium featuring discussion of significant new data sets, promising treatment strategies and key interdisciplinary management considerations in the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic, ovarian and select hematologic cancers. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This activity has been designed to meet the educational needs of medical oncologists, hematologists, hematology-oncology fellows and other allied cancer professionals.

    LEARNING OBJECTIVES

    • Effectively apply the results of practice-changing clinical research to the care of patients with breast, lung, head and neck, gastrointestinal, genitourinary, dermatologic, gynecologic and select hematologic cancers.
    • Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences.
    • Recall ongoing trials in breast, lung, head and neck, gastrointestinal, genitourinary, dermatologic, gynecologic and select hematologic cancers, and refer appropriate patients for study participation.
    • Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer.
    • Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies.
    • Refine or validate existing cancer-specific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators.
    • Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 14.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 14.75 Medical Knowledge MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    Please note, this program has been specifically designed for the following ABIM specialties: medical oncology and hematology.

    Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

    HOW TO USE THIS CME ACTIVITY
    This CME activity consists of a video component. To receive credit, the participant should review the CME information, watch the video, complete the Post-test with a score of 80% or better and fill out the Educational Assessment and Credit Form located at ResearchToPractice.com/GMO20/CME.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported relevant conflicts of interest, which have been resolved through a conflict of interest resolution process:

    Jeremy Abramson, MD
    Director, Center for Lymphoma
    Massachusetts General Hospital
    Associate Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Consulting Agreements: AbbVie Inc, Allogene Therapeutics, Celgene Corporation, EMD Serono Inc, Genentech, a member of the Roche Group, Janssen Biotech Inc, Karyopharm Therapeutics, Kite Pharma Inc, MorphoSys, Novartis, Roche Laboratories Inc; Contracted Research: Celgene Corporation, Seattle Genetics.

    Tanios Bekaii-Saab, MD
    Professor, Mayo Clinic College of Medicine and Science
    Program Leader, Gastrointestinal Cancer, Mayo Clinic Cancer Center
    Vice-Chair and Section Lead, Division of Medical Oncology
    Medical Director, Cancer Clinical Research Office
    Senior Associate Consultant
    Mayo Clinic
    Phoenix, Arizona

    Advisory Committee: Amgen Inc, Immuneering Corporation, Imugene; Consulting Agreements: AbbVie Inc, Array BioPharma Inc, Bayer HealthCare Pharmaceuticals; Contracted Research: Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, Astellas, Bayer HealthCare Pharmaceuticals, Boston Biomedical Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Ipsen Biopharmaceuticals Inc, Novartis; Data and Safety Monitoring Board/Committee: ARMO BioSciences, AstraZeneca Pharmaceuticals LP, Exelixis Inc, Merck, SillaJen.

    Johanna Bendell, MD
    Chief Development Officer
    Director, Drug Development Unit Nashville
    Sarah Cannon Research Institute
    Tennessee Oncology
    Nashville, Tennessee

    Consulting Agreements: Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, ARMO BioSciences, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, BeiGene, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Continuum Clinical, Cyteir Therapeutics, Daiichi Sankyo Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, Merck, Merrimack Pharmaceuticals Inc, Moderna Inc, Molecular Partners, Novartis, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc, PhoenixBio, Prelude Therapeutics, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Taiho Oncology Inc, Tanabe Research Laboratories, TG Therapeutics Inc, Tizona Therapeutics Inc, Tolero Pharmaceuticals, Torque Therapeutics, Translational Drug Development; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, ADC Therapeutics SA, Agios Pharmaceuticals Inc, Amgen Inc, Apexigen, Arch Oncology, Arcus Biosciences, ARMO BioSciences, Array BioPharma Inc, Arrys Therapeutics, a wholly owned subsidiary of Kyn Therapeutics, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bellicum Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Calithera Biosciences, Celgene Corporation, Celldex Therapeutics, CytomX Therapeutics, Daiichi Sankyo Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, FORMA Therapeutics, Forty Seven Inc, Genentech, a member of the Roche Group, Gilead Sciences Inc, GlaxoSmithKline, Gossamer Bio, Harpoon Therapeutics, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Incyte Corporation, Innate Pharma, Ipsen Biopharmaceuticals Inc, Jacobio Pharmaceuticals Co Ltd, Kolltan Pharmaceuticals Inc, Leap Therapeutics Inc, Lilly, MacroGenics Inc, MEI Pharma Inc, Merck, Merrimack Pharmaceuticals Inc, Mersana Therapeutics, Merus BV, Nektar, Novartis, Novocure, OncoGenex Pharmaceuticals Inc, OncoMed Pharmaceuticals Inc, Onyx Pharmaceuticals, an Amgen subsidiary, Pfizer Inc, Pieris Pharmaceuticals Inc, Prelude Therapeutics, Rgenix, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics, Shattuck Labs, Sierra Oncology, SynDevRx Inc, Taiho Oncology Inc, Takeda Oncology, Tarveda Therapeutics, Tempest Therapeutics Inc, TG Therapeutics Inc, TRACON Pharmaceuticals Inc, Tyrogenex Inc, Unum Therapeutics, Vyriad; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc.

    Michael J Birrer, MD, PhD
    Director, Winthrop P Rockefeller Cancer Institute
    Director, Cancer Service Line
    University of Arkansas
    Little Rock, Arkansas

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Clovis Oncology, Tesaro, A GSK Company.

    Hossein Borghaei, MS, DO
    Professor and Chief, Thoracic Oncology
    The Gloria and Edmund M Dunn Chair in Thoracic Oncology
    Fox Chase Cancer Center
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Amgen Inc, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, EMD Serono Inc, Genentech, a member of the Roche Group, Genmab, Lilly, Merck, Novartis, Pfizer Inc, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Axiom Life Sciences Group LLC, Bristol-Myers Squibb Company, HUYA Bioscience International, Lilly, Merck; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck, Takeda Oncology; Data and Safety Monitoring Board/Committee: Incyte Corporation, Takeda Oncology, University of Pennsylvania, Vanderbilt University; Scientific Advisory Board: Rgenix, Sonnet BioTherapeutics.

    Harold J Burstein, MD, PhD
    Professor of Medicine
    Harvard Medical School
    Breast Oncology Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    No financial interests or affiliations to disclose.

    Barbara Burtness, MD
    Professor of Medicine
    Yale School of Medicine
    Co-Leader, Developmental Therapeutics Program
    Yale Cancer Center
    New Haven, Connecticut

    Advisory Committee: Aduro Biotech, ALX Oncology, Celgene Corporation, Cue Biopharma, Merck, Nanobiotix, Oncolys BioPharma, Rakuten Medical; Consulting Agreement: Celgene Corporation; Contracted Research: Aduro Biotech, Bristol-Myers Squibb Company, Celldex Therapeutics, Forbius, Merck; Data and Safety Monitoring Board/Committee: IDDI, Kura Oncology.

    Matthew S Davids, MD, MMSc
    Assistant Professor of Medicine, Harvard Medical School
    Director, DFCI Lymphoma BioBank
    Associate Director, CLL Center
    Dana-Farber Cancer Institute
    Boston, Massachusetts

    Advisory Committee: AbbVie Inc, Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Pharmacyclics LLC, an AbbVie Company, TG Therapeutics Inc; Consulting Agreements: AbbVie Inc, Adaptive Biotechnologies, AstraZeneca Pharmaceuticals LP, BeiGene, Genentech, a member of the Roche Group, Janssen Biotech Inc, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Sunesis Pharmaceuticals Inc, Verastem Inc; Contracted Research: Ascentage Pharma, AstraZeneca Pharmaceuticals LP, Genentech, a member of the Roche Group, MEI Pharma Inc, Pharmacyclics LLC, an AbbVie Company, Surface Oncology, TG Therapeutics Inc, Verastem Inc.

    Robert Dreicer, MD, MS
    Section Head, Medical Oncology
    Deputy Director, University of Virginia Cancer Center
    Associate Director for Clinical Research
    Professor of Medicine and Urology
    University of Virginia School of Medicine
    Charlottesville, Virginia

    Advisory Committee: Astellas, Eisai Inc, Janssen Biotech Inc, Novartis, Orion Corporation, Pfizer Inc, Seattle Genetics, Vizuri Health Sciences; Contracted Research: Bristol-Myers Squibb Company, Exelixis Inc, Pfizer Inc, Seattle Genetics.

    Jonathan W Friedberg, MD, MMSc
    Samuel E Durand Professor of Medicine
    Director, James P Wilmot Cancer Institute
    University of Rochester
    Rochester, New York

    Data and Safety Monitoring Board/Committee: Acerta Pharma — A member of the AstraZeneca Group, Bayer HealthCare Pharmaceuticals.

    Charles E Geyer Jr, MD
    Deputy Director
    Houston Methodist Cancer Center
    Houston, Texas

    Advisory Committee (Uncompensated): Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc, Seattle Genetics; Contracted Research: Genentech, a member of the Roche Group, Roche Laboratories Inc; Paid Travel: AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc; Writing Assistance: AbbVie Inc, Genentech, a member of the Roche Group, Roche Laboratories Inc.

    Erika Hamilton, MD
    Director, Breast and Gynecologic Research Program
    Sarah Cannon Research Institute
    Nashville, Tennessee

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Lilly, Mersana Therapeutics, NanoString Technologies, Novartis, Pfizer Inc, Puma Biotechnology Inc, Silverback Therapeutics; Contracted Research: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Aravive Inc, ArQule Inc, Arvinas, AstraZeneca Pharmaceuticals LP, BerGenBio ASA, Black Diamond Therapeutics Inc, Boehringer Ingelheim Pharmaceuticals Inc, Clovis Oncology, Compugen, Curis Inc, CytomX Therapeutics, Daiichi Sankyo Inc, Deciphera Pharmaceuticals Inc, eFFECTOR Therapeutics Inc, Eisai Inc, EMD Serono Inc, Fochon Pharmaceuticals Ltd, Fosun Orinove PharmaTech Inc, FUJIFILM Pharmaceuticals USA Inc, G1 Therapeutics, Genentech, a member of the Roche Group, H3 Biomedicine, Harpoon Therapeutics, Hutchison MediPharma, Immunomedics Inc, InventisBio, Karyopharm Therapeutics, Leap Therapeutics Inc, Lilly, Lycera, MacroGenics Inc, Marker Therapeutics Inc, Medivation Inc, a Pfizer Company, Mersana Therapeutics, Merus BV, Molecular Templates, Novartis, NuCana, OncoMed Pharmaceuticals Inc, Pfizer Inc, Puma Biotechnology Inc, Radius Health Inc, Regeneron Pharmaceuticals Inc, Rgenix, Seattle Genetics, Sermonix Pharmaceuticals, Silverback Therapeutics, Stemcentrx, Sutro Biopharma, Syndax Pharmaceuticals Inc, Syros Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Torque Therapeutics, Unum Therapeutics, Verastem Inc, Zenith Epigenetics Ltd, Zymeworks.

    Leora Horn, MD, MSc
    Ingram Associate Professor of Cancer Research
    Director, Thoracic Oncology Research Program
    Assistant Vice Chairman for Faculty Development
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Committee: EMD Serono Inc, Genentech, a member of the Roche Group, Xcovery; Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, EMD Serono Inc, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Pfizer Inc, Roche Laboratories Inc, Tesaro, A GSK Company, Xcovery; Contracted Research: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Genentech, a member of the Roche Group, Incyte Corporation, Merck, Takeda Oncology, Xcovery; Paid Travel: Bristol-Myers Squibb Company, Xcovery.

    Virginia Kaklamani, MD, DSc
    Professor of Medicine
    Ruth McLean Bowman Bowers Chair in Breast Cancer Research and Treatment
    AB Alexander Distinguished Chair in Oncology
    Associate Director for Clinical Research
    Leader of the Breast Cancer Program
    UT Health San Antonio
    The University of Texas MD Anderson Cancer Center
    San Antonio, Texas

    Consulting Agreements: Amgen Inc, AstraZeneca Pharmaceuticals LP, Athenex, Celldex Therapeutics, Eisai Inc, Puma Biotechnology Inc; Contracted Research: Eisai Inc; Speakers Bureau: Celgene Corporation, Eisai Inc, Genentech, a member of the Roche Group, Genomic Health Inc, Novartis, Pfizer Inc, Puma Biotechnology Inc.

    Stephen V Liu, MD, PhD
    Associate Professor of Medicine
    Georgetown University Hospital
    Washington, DC

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Celgene Corporation, G1 Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, PharmaMar, Regeneron Pharmaceuticals Inc, Takeda Oncology; Consulting Agreements: AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Janssen Biotech Inc, Lilly, Merck, Merck Sharp & Dohme Corp, Pfizer Inc, Takeda Oncology; Contracted Research: Alkermes, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Blueprint Medicines, Bristol-Myers Squibb Company, Corvus Pharmaceuticals, Genentech, a member of the Roche Group, Lilly, Lycera, Merck, Merus BV, Molecular Partners, Pfizer Inc, Rain Therapeutics, RAPT Therapeutics, Spectrum Pharmaceuticals Inc, Turning Point Therapeutics; Data and Safety Monitoring Board/Committee: Taiho Oncology Inc.

    Sagar Lonial, MD
    Chair and Professor
    Department of Hematology and Medical Oncology
    Chief Medical Officer
    Winship Cancer Institute
    Emory University
    Atlanta, Georgia

    Consulting Agreements: Amgen Inc, Bristol-Myers Squibb Company, Celgene Corporation, GlaxoSmithKline, Janssen Biotech Inc, Novartis, Takeda Oncology; Contracted Research: Celgene Corporation, Janssen Biotech Inc, Takeda Oncology.

    Jason J Luke, MD
    Associate Professor and Director of the Cancer Immunotherapeutics Center
    University of Pittsburgh Medical Center and
    Hillman Cancer Center
    Pittsburgh, Pennsylvania

    Advisory Committee: 7 Hills Pharma LLC, AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Spring Bank Pharmaceuticals Inc, Tempest Therapeutics Inc; Consulting Agreements: AbbVie Inc, Akrevia Therapeutics, Aligos Therapeutics, Array BioPharma Inc, Astellas, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Eisai Inc, EMD Serono Inc, IDEAYA Biosciences, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, RefleXion, Silicon Therapeutics, Tesaro, A GSK Company, Vividion Therapeutics; Contracted Research: AbbVie Inc, Agios Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Checkmate Pharmaceuticals, Compugen Inc, Corvus Pharmaceuticals, EMD Serono Inc, Evelo Biosciences Inc, Five Prime Therapeutics Inc, Genentech, a member of the Roche Group, Immatics Biotechnologies GmbH, Immunocore , Incyte Corporation, Leap Therapeutics Inc, MacroGenics Inc, Merck, Nektar, Novartis, Palleon Pharmaceuticals, RAPT Therapeutics, Spring Bank Pharmaceuticals Inc, Tesaro, A GSK Company, Tizona Therapeutics Inc, Xencor; Data and Safety Monitoring Board/Committee: TTC Oncology; Paid Travel: Akrevia Therapeutics, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, EMD Serono Inc, Incyte Corporation, Janssen Biotech Inc, Merck, Mersana Therapeutics, Novartis, Pyxis Oncology, RefleXion; Ownership Interest: AbbVie Inc, Actym Therapeutics, Alphamab Oncology, Pyxis Oncology, Tempest Therapeutics Inc.

    John L Marshall, MD
    Chief, Hematology and Oncology
    Director, Ruesch Center for the Cure of GI Cancers
    Lombardi Comprehensive Cancer Center
    Georgetown University
    Washington, DC

    Advisory Committee, Consulting Agreements and Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Caris Life Sciences, Celgene Corporation, Indivumed GmbH, Roche Laboratories Inc, Taiho Oncology Inc; Speakers Bureau: Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Merck, Roche Laboratories Inc, Taiho Oncology Inc.

    Anthony R Mato, MD, MSCE
    Associate Attending
    Director, Chronic Lymphocytic Leukemia Program
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee and Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Celgene Corporation, Genentech, a member of the Roche Group, Johnson & Johnson Pharmaceuticals, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Octapharma, Pharmacyclics LLC, an AbbVie Company, Regeneron Pharmaceuticals Inc, Sunesis Pharmaceuticals Inc, TG Therapeutics Inc; Contracted Research: Celgene Corporation, Genentech, a member of the Roche Group, Pharmacyclics LLC, an AbbVie Company; Data and Safety Monitoring Board/Committee: Celgene Corporation, TG Therapeutics Inc.

    Wells A Messersmith, MD
    Professor and Head, Division of Medical Oncology
    Associate Director for Translational Research
    University of Colorado Cancer Center
    Aurora, Colorado

    Contracted Research: Aduro Biotech, ALX Oncology, AstraZeneca Pharmaceuticals LP, BeiGene, D3 Pharma, Gossamer Bio, Immunomedics Inc, OncoMed Pharmaceuticals Inc, Pfizer Inc; Data and Safety Monitoring Board/Committee: Five Prime Therapeutics Inc, QED Therapeutics.

    Kathleen Moore, MD
    The Virginia Kerley Cade Endowed Chair in Cancer Development
    Associate Director, Clinical Research
    Director, Oklahoma TSET Phase I Program
    Stephenson Cancer Center
    Associate Professor, Section of Gynecologic Oncology
    Director, Gynecologic Oncology Fellowship
    Department of Obstetrics and Gynecology
    University of Oklahoma Health Sciences Center
    Oklahoma City, Oklahoma

    Advisory Committee: AbbVie Inc, Aravive Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, ImmunoGen Inc, Merck, Mereo BioPharma, Tarveda Therapeutics, Tesaro, A GSK Company, Vavotar Life Sciences; Contracted Research: Clovis Oncology, Genentech, a member of the Roche Group, Merck, PTC Therapeutics; Employment: GOG Foundation/Partners.

    William K Oh, MD
    Chief, Division of Hematology and Medical Oncology
    Professor of Medicine and Urology
    Ezra M Greenspan, MD Professor in Clinical Cancer Therapeutics
    Icahn School of Medicine at Mount Sinai
    Associate Director of Clinical Research
    The Tisch Cancer Institute
    Mount Sinai Health System
    New York, New York

    Consulting Agreements: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, CPS Companion Diagnostics, Janssen Biotech Inc, Sanofi Genzyme, Sema4, TeneoBio.

    Alexander Perl, MD
    Associate Professor of Medicine
    Perelman School of Medicine at the University of Pennsylvania
    Member, Leukemia Program
    Abramson Cancer Center of the University of Pennsylvania
    Philadelphia, Pennsylvania

    Advisory Committee: AbbVie Inc, Actinium Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc, FORMA Therapeutics, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, NewLink Genetics; Consulting Agreements: AbbVie Inc, Arog Pharmaceuticals Inc, Astellas, Daiichi Sankyo Inc; Contracted Research: AbbVie Inc, Astellas, Bayer HealthCare Pharmaceuticals, Daiichi Sankyo Inc, FUJIFILM Pharmaceuticals USA Inc; Data and Safety Monitoring Board/Committee: Leukemia & Lymphoma Society.

    Daniel P Petrylak, MD
    Professor of Internal Medicine (Medical Oncology) and Urology
    Yale University
    New Haven, Connecticut

    Consulting Agreements: Advanced Accelerator Applications, Amgen Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bicycle Therapeutics, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Clovis Oncology, Exelixis Inc, Incyte Corporation, Janssen Biotech Inc, Lilly, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Roche Laboratories Inc, Seattle Genetics, UroGen Pharma; Contracted Research: Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Clovis Oncology, Endocyte Inc, Genentech, a member of the Roche Group, Innocrin Pharmaceuticals Inc, Lilly, Merck, Novartis, Pfizer Inc, Progenics Pharmaceuticals Inc, Roche Laboratories Inc, Sanofi Genzyme, Seattle Genetics; Ownership Interest: Bellicum Pharmaceuticals Inc, Tyme Inc.

    Paul G Richardson, MD
    Clinical Program Leader
    Director of Clinical Research
    Jerome Lipper Multiple Myeloma Center
    Department of Medical Oncology
    Dana-Farber Cancer Institute
    RJ Corman Professor of Medicine
    Harvard Medical School
    Boston, Massachusetts

    Advisory Committee: Celgene Corporation, Janssen Biotech Inc, Karyopharm Therapeutics, Oncopeptides, Sanofi Genzyme, Takeda Oncology; Contracted Research: Bristol-Myers Squibb Company, Celgene Corporation, Oncopeptides, Takeda Oncology.

    Gregory J Riely, MD, PhD
    Associate Attending
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Contracted Research: Merck, Mirati Therapeutics, Novartis, Pfizer Inc, Roche Laboratories Inc, Takeda Oncology.

    Kerry Rogers, MD
    Assistant Professor in the Division of Hematology
    The Ohio State University
    Columbus, Ohio

    Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Pharmacyclics LLC, an AbbVie Company; Contracted Research: AbbVie Inc, Genentech,  a member of the Roche Group, Janssen Biotech Inc; Paid Travel: AstraZeneca Pharmaceuticals LP.

    Tanguy Y Seiwert, MD
    Director, Head and Neck Cancer Oncology Disease Group
    Co-Director, Bloomberg-Kimmel Institute for Immunotherapy — HNC Program
    Assistant Professor of Oncology and Otolaryngology
    Johns Hopkins University
    Baltimore, Maryland

    Advisory Committee: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Cue Biopharma, Innate Pharma, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Maverick Therapeutics, Merck, Merck Sharp & Dohme Corp, Nanobiotix, Roche Diagnostics; Ownership Interest: SQZ Biotech.

    Matthew R Smith, MD, PhD
    Claire and John Bertucci Endowed Chair in Genitourinary Cancers
    Professor of Medicine
    Harvard Medical School
    Director, Genitourinary Malignancies Program
    Massachusetts General Hospital Cancer Center
    Boston, Massachusetts

    Advisory Committee and Consulting Agreements: Amgen Inc, Astellas, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly; Contracted Research: Amgen Inc, Bayer HealthCare Pharmaceuticals, Clovis Oncology, Janssen Biotech Inc, Lilly.

    Mitchell R Smith, MD, PhD
    Professor of Medicine
    Associate Center Director for Clinical Investigations
    Director, Division of Hematology and Oncology
    GW Cancer Center
    Washington, DC

    Data and Safety Monitoring Board/Committee: Eastern Cooperative Oncology Group; Speakers Bureau: AstraZeneca Pharmaceuticals LP, EUSA Pharma.

    Sonali M Smith, MD
    Elwood V Jensen Professor of Medicine
    Interim Chief, Section of Hematology/Oncology
    Director, Lymphoma Program
    The University of Chicago
    Chicago, Illinois

    Consulting Agreements: Bayer HealthCare Pharmaceuticals, Celgene Corporation, Genentech, a member of the Roche Group, TG Therapeutics Inc; Contracted Research: Acerta Pharma — A member of the AstraZeneca Group, Celgene Corporation, Curis Inc, Forty Seven Inc, Genentech, a member of the Roche Group, Novartis, Portola Pharmaceuticals Inc, Seattle Genetics, TG Therapeutics Inc; Honorarium: Genentech, a member of the Roche Group.

    Eytan M Stein, MD
    Assistant Attending Physician
    Director, Center for Drug Development in Leukemia
    Leukemia Service, Department of Medicine
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Agios Pharmaceuticals Inc, Amgen Inc, Astellas, Celgene Corporation, Daiichi Sankyo Inc, Genentech, a member of the Roche Group, Menarini Group, Novartis, PTC Therapeutics, Seattle Genetics, Syros Pharmaceuticals Inc; Contracted Research: Agios Pharmaceuticals Inc, Amgen Inc, Bayer HealthCare Pharmaceuticals, Celgene Corporation, Syros Pharmaceuticals Inc; Data and Safety Monitoring Board/Committee: Cellectis, Epizyme; Ownership Interest: Auron Therapeutics.

    Jeffrey S Weber, MD, PhD
    Deputy Director
    Laura and Isaac Perlmutter Cancer Center
    Professor of Medicine
    NYU Langone Medical Center
    New York, New York

    Consulting Agreements: Altor Bioscience Corp, Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Biond Biologics, Blueprint Medicines, Bristol-Myers Squibb Company, Celldex Therapeutics, CytomX Therapeutics, Genentech, a member of the Roche Group, GlaxoSmithKline, Incyte Corporation, Merck, Pfizer Inc, Protean LLC, Sellas Life Sciences, Takeda Oncology; Contracted Research: NextCure; Data and Safety Monitoring Board/Committee: Pfizer Inc; Ownership Interest: Altor Bioscience Corp, Biond Biologics, CytomX Therapeutics, Protean LLC; Other: Named on a patent for a PD-1 biomarker by Biodesix Inc, and for a CTLA-4 biomarker by Moffitt Cancer Center.

    MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Acerta Pharma — A member of the AstraZeneca Group, Adaptive Biotechnologies, Agendia Inc, Agios Pharmaceuticals Inc, Amgen Inc, Ariad Pharmaceuticals Inc, Array BioPharma Inc, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, bioTheranostics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Pharmaceuticals Inc, Eisai Inc, EMD Serono Inc, Exelixis Inc, Foundation Medicine, Genentech, a member of the Roche Group, Genmab, Genomic Health Inc, Gilead Sciences Inc, GlaxoSmithKline, Guardant Health, Halozyme Inc, ImmunoGen Inc, Incyte Corporation, Infinity Pharmaceuticals Inc, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Kite, A Gilead Company, Lexicon Pharmaceuticals Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Merrimack Pharmaceuticals Inc, Myriad Genetic Laboratories Inc, Natera Inc, Novartis, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sandoz Inc, a Novartis Division, Sanofi Genzyme, Seattle Genetics, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Tesaro, A GSK Company, Teva Oncology, Tokai Pharmaceuticals Inc and Tolero Pharmaceuticals.

    RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Amgen Inc, Array BioPharma Inc, Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Eisai Inc, Genentech, a member of the Roche Group, GlaxoSmithKline, Lilly, Merck, Novartis, Oncopeptides, Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, administered by Janssen Scientific Affairs LLC, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi Genzyme, Seattle Genetics, and Taiho Oncology Inc.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 11 or later, Firefox 56 or later, Chrome 61 or later, Safari 11 or later, Opera 48 or later
    Adobe Flash Player 27 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Release date: April 2020
    Expiration date: April 2021

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Watch videos
(WIFI is recommended for best performance):

Keynote Session: Chronic Lymphocytic Leukemia (CLL)

Colorectal and Gastric Cancer

Hepatocellular Carcinoma and Pancreatic Cancer

Dermatologic Cancers

Hodgkin and Non-Hodgkin Lymphomas

Diffuse Large B-Cell Lymphoma (DLBCL)/Chimeric Antigen Receptor (CAR) T-Cell Therapy

Acute Leukemias

Gynecologic Cancers

ER-Positive, HER2-Negative Breast Cancer

HER2-Positive and Triple-Negative Breast Cancer

Prostate Cancer (PC)

Renal Cell Carcinoma and Bladder Cancer

Head and Neck Cancer

Multiple Myeloma (MM)

Immune Checkpoint Inhibitors in Lung Cancer

Targeted Treatment of Lung Cancer

Select Publications